Brian Cihlar
Associate at Hancock Capital Management, LLC
Chicago, Illinois
Brian Cihlar, Associate at Hancock Capital Management, LLC is an active investor based in Chicago, Illinois. This profile covers what Brian Cihlar backs, at which stage, and how founders can reach out in 2026.
- Investor type
- VCVenture Debt
- Stages
- SeedSeries ASeries BLate Stage Venture
- Location
- Chicago, Illinois
- Typical check
- $2M
How to reach Brian Cihlar
Angels and operators like Brian Cihlar reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.
Connect with Brian Cihlar
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise.
Frequently Asked Questions
Who is Brian Cihlar?
Brian Cihlar is an active investor, Associate at Hancock Capital Management, LLC. Round Funded tracks their focus and activity alongside thousands of investors.
What stage does Brian Cihlar invest at?
Brian Cihlar typically invests at Seed, Series A, Series B and Late Stage Venture. Lead with traction that fits the stage when you reach out.
What is Brian Cihlar's typical check size?
Brian Cihlar typically writes checks around $2M. Use it as a signal for whether your raise fits their stage.
How do I contact Brian Cihlar?
Unlock Brian Cihlar's verified email on Round Funded and send a personalized pitch. We surface only deliverable contacts so your outreach lands.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.